Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide

Shinji Ohie, Yasuhiro Udagawa, Akiko Kozu, Yuki Komuro, Daisuke Aoki, Shiro Nozawa, A. R. Moossa, Robert M. Hoffman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The histoculture drug sensitivity assay (HDRA) has been demonstrated to have high predictability for resistance, sensitivity, and survival for gastrointestinal cancer. In this report, we evaluated the clinical usefulness of the HDRA in ovarian cancer. HDRA was performed on tumors from patients with ovarian cancer. Eighty-five cases (97%) were evaluable. Tumor fragments were cultured on collagen-sponge gels. The cultures were incubated with cisplatin (CDDP) for seven days. Cell viability were assessed with the MTT endpoint. The optimal cut off concentration of CDDP was determined to be 25 μg/ml by correlation with the historical clinical response rate to CDDP. HDRA results were correlated to clinical response of 15 patients who received CDDP-based therapy that included doxorubicin and cyclophosphamide (CAP therapy). The true positive rate was 88%, the true negative rate was 86%, the sensitivity was 88%, the specificity was 86%, and the accurate prediction rate was 87% when HDRA results were compared to the response of the treated patients. The data suggest that the HDRA is capable of predicting the response to antitumor chemotherapy in patients with ovarian cancer and that measuring response to CDDP can be useful for optimization of CAP chemotherapy for patients with this disease.

Original languageEnglish
Pages (from-to)2049-2054
Number of pages6
JournalAnticancer Research
Volume20
Issue number3 B
Publication statusPublished - 2000

Fingerprint

Combination Drug Therapy
Ovarian Neoplasms
Doxorubicin
Cyclophosphamide
Cisplatin
Pharmaceutical Preparations
Drug Therapy
Gastrointestinal Neoplasms
Porifera
Neoplasms
Cell Survival
Collagen
Gels
Survival
Therapeutics

Keywords

  • Cisplatin
  • Clinical correlation
  • Cyclophosphamide
  • Doxorubicin
  • Histoculture drug response assay
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. / Ohie, Shinji; Udagawa, Yasuhiro; Kozu, Akiko; Komuro, Yuki; Aoki, Daisuke; Nozawa, Shiro; Moossa, A. R.; Hoffman, Robert M.

In: Anticancer Research, Vol. 20, No. 3 B, 2000, p. 2049-2054.

Research output: Contribution to journalArticle

Ohie, Shinji ; Udagawa, Yasuhiro ; Kozu, Akiko ; Komuro, Yuki ; Aoki, Daisuke ; Nozawa, Shiro ; Moossa, A. R. ; Hoffman, Robert M. / Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. In: Anticancer Research. 2000 ; Vol. 20, No. 3 B. pp. 2049-2054.
@article{f996977ddc4747358a04bb40e349499c,
title = "Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide",
abstract = "The histoculture drug sensitivity assay (HDRA) has been demonstrated to have high predictability for resistance, sensitivity, and survival for gastrointestinal cancer. In this report, we evaluated the clinical usefulness of the HDRA in ovarian cancer. HDRA was performed on tumors from patients with ovarian cancer. Eighty-five cases (97{\%}) were evaluable. Tumor fragments were cultured on collagen-sponge gels. The cultures were incubated with cisplatin (CDDP) for seven days. Cell viability were assessed with the MTT endpoint. The optimal cut off concentration of CDDP was determined to be 25 μg/ml by correlation with the historical clinical response rate to CDDP. HDRA results were correlated to clinical response of 15 patients who received CDDP-based therapy that included doxorubicin and cyclophosphamide (CAP therapy). The true positive rate was 88{\%}, the true negative rate was 86{\%}, the sensitivity was 88{\%}, the specificity was 86{\%}, and the accurate prediction rate was 87{\%} when HDRA results were compared to the response of the treated patients. The data suggest that the HDRA is capable of predicting the response to antitumor chemotherapy in patients with ovarian cancer and that measuring response to CDDP can be useful for optimization of CAP chemotherapy for patients with this disease.",
keywords = "Cisplatin, Clinical correlation, Cyclophosphamide, Doxorubicin, Histoculture drug response assay, Ovarian cancer",
author = "Shinji Ohie and Yasuhiro Udagawa and Akiko Kozu and Yuki Komuro and Daisuke Aoki and Shiro Nozawa and Moossa, {A. R.} and Hoffman, {Robert M.}",
year = "2000",
language = "English",
volume = "20",
pages = "2049--2054",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide

AU - Ohie, Shinji

AU - Udagawa, Yasuhiro

AU - Kozu, Akiko

AU - Komuro, Yuki

AU - Aoki, Daisuke

AU - Nozawa, Shiro

AU - Moossa, A. R.

AU - Hoffman, Robert M.

PY - 2000

Y1 - 2000

N2 - The histoculture drug sensitivity assay (HDRA) has been demonstrated to have high predictability for resistance, sensitivity, and survival for gastrointestinal cancer. In this report, we evaluated the clinical usefulness of the HDRA in ovarian cancer. HDRA was performed on tumors from patients with ovarian cancer. Eighty-five cases (97%) were evaluable. Tumor fragments were cultured on collagen-sponge gels. The cultures were incubated with cisplatin (CDDP) for seven days. Cell viability were assessed with the MTT endpoint. The optimal cut off concentration of CDDP was determined to be 25 μg/ml by correlation with the historical clinical response rate to CDDP. HDRA results were correlated to clinical response of 15 patients who received CDDP-based therapy that included doxorubicin and cyclophosphamide (CAP therapy). The true positive rate was 88%, the true negative rate was 86%, the sensitivity was 88%, the specificity was 86%, and the accurate prediction rate was 87% when HDRA results were compared to the response of the treated patients. The data suggest that the HDRA is capable of predicting the response to antitumor chemotherapy in patients with ovarian cancer and that measuring response to CDDP can be useful for optimization of CAP chemotherapy for patients with this disease.

AB - The histoculture drug sensitivity assay (HDRA) has been demonstrated to have high predictability for resistance, sensitivity, and survival for gastrointestinal cancer. In this report, we evaluated the clinical usefulness of the HDRA in ovarian cancer. HDRA was performed on tumors from patients with ovarian cancer. Eighty-five cases (97%) were evaluable. Tumor fragments were cultured on collagen-sponge gels. The cultures were incubated with cisplatin (CDDP) for seven days. Cell viability were assessed with the MTT endpoint. The optimal cut off concentration of CDDP was determined to be 25 μg/ml by correlation with the historical clinical response rate to CDDP. HDRA results were correlated to clinical response of 15 patients who received CDDP-based therapy that included doxorubicin and cyclophosphamide (CAP therapy). The true positive rate was 88%, the true negative rate was 86%, the sensitivity was 88%, the specificity was 86%, and the accurate prediction rate was 87% when HDRA results were compared to the response of the treated patients. The data suggest that the HDRA is capable of predicting the response to antitumor chemotherapy in patients with ovarian cancer and that measuring response to CDDP can be useful for optimization of CAP chemotherapy for patients with this disease.

KW - Cisplatin

KW - Clinical correlation

KW - Cyclophosphamide

KW - Doxorubicin

KW - Histoculture drug response assay

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0033884312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033884312&partnerID=8YFLogxK

M3 - Article

C2 - 10928150

AN - SCOPUS:0033884312

VL - 20

SP - 2049

EP - 2054

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -